The growing use of dietary supplements, often combined with conventional drugs, creates a possibility of adverse reactions and interactions and asks for their safe application. The majority of patients do not disclose the use of dietary supplements to doctors; physicians are not always informed about the adoption of supplements and are often reluctant to initiate discussion on this topic. This lack of physician-patient comunication leads to an increased risk of the dietary supplements use. PURPOSE: То еstablish some of physician-patient communication problems on the use of dietary supplements. METHODS: This is a pilot study on the use of dietary supplements among the population of the town Stara Zagora. The pilot study was conducted by self-administrated questionnaire on people aged 19 to 59 years (n = 24). RESULTS: The opinion of 45.8% of all respondents in this pilot study is that when visiting doctors they have never been asked about the use of dietary supplements.78.8% of users of dietary supplements in the study did not tend to spontaneously share with their physicians that they accept food supplements. CONCLUSION: The low level of communication on the use of dietary supplements highlights the need for a new type of physician-patient relationships in order to reduce the risks associated with the use of dietary supplements.
INTRODUCTION
Over the last few decades, higher interest and increasing use of dietary suppplements (DS) has been observed worldwide. (1) (2) (3) According to the European Directive 2002/46/EU, 'food (dietary) supplements' refers to food stuffs whose purpose is to supplement the normal diet and which are concentrated sources of nutrients or other substances with nutritional or physiological effect, alone or in combination, and which are _________________________ marketed in dose form, such as capsules, pastilles, tablets, pills and other similar forms, sachets of powder, ampoules of liquids, drop dispensing bottles, and other similar forms of liquids and powders, all designed to be taken in measured small unit quantities. (4) Similar is the definition of DS given by DSHEA in the USA. (5) In analyses of the socio-demographic characteristics of consumers, a general profile emerges, whereby the representatives of the female sex, people belonging to the white race, people with higher education levels and higher incomes are more likely to use DS. (3) Among one group of users, the main reason for taking HD is "maintaining the overall health and well-being". (6) (7) (8) This group of people aspires to a healthy lifestyle, including good diet, regular exercise, healthy weight maintenance and tobacco avoidance. They define their health as very good or excellent and, in this sense the use of DS is an expression of the desire to remain healthy and only one component of efforts to lead a healthy lifestyle. (8) Among another group of patients, DS intake is associated with the presence of other, more common chronic diseases, so that in these cases DS may be in the role of alternative or complementary conventional therapy agents.The use of DS as an alternative means of treatment can lead to the delay of appropriate, effective conventional therapies and threaten the health of patients. (9) The use of DS as complementary care is also unsafe, despite consumers' belief that these products are harmless due to their natural origin. (10) With increasing use, evidence has accumulated to suggest that the use of DS, especially plantbased ones, is associated with variedly severe adverse reactions, in turn related to the presence of multiple active components. (11) (12) (13) (14) A small portion of patients are aware of the fact that DS are not subject to the same strict regulation as conventional drugs, often lack evidence of efficacy and safety, and in many cases lack quality guarantees of these products. In recent years, several studies have been devoted to clarifying the weaknesses in the regulation of supplements and the possibility of allowing adulteration, substitution, contamination, misidentification, lack of standardization, incorrect preparation and/or dosage and inappropriate labeling. (12, 15) In patients with chronic diseases who receive one or more prescribed medications, the risk of DS use is also associated with the possibility of interactions between DS and other received medicines, many of which have already been documented. (16, 17) In addition to those risk factors, frequent use of DS occurs by personal initiative and choice, rather than by recommendation of physicians and other health care professionals. (6) Majority of patients do not inform their physicians about intake such products. "Selfprescription" of DS, concomitant use with drugs, and failure to disclose DS intake to doctors all increase the risk of health problems and raise concern for patients. Safe integration of DS in modern therapeutic regimens requires open doctor-patient discussion to clarify the use or intention to use DS and the benefits and risks associated with these products, and to support informed decision-making by the patient.
PURPOSE
The purpose of this study is to establish some problems of physician-patient communication related to the use of DS.
MATERIAL AND METHODS
The study represents some of the results from a pilot study on the use of DS among the population of town Stara Zagora conducted between July and August 2014 with the participation of 24 people (10 men and 14 women), aged 19-59 years. An individual selfadministrated questionnaire was used to gather the information about DS intake within the past year, observing the principles of anonymity and voluntariness. A part of questions assessed some communication patterns related to DS use: respondents' disclosure of DS use, reasons for nondisclosure and frequency of physicians' interest on the use of DS. Descriptive statistics was employed to examine the data. Data analysis was conducted using SPSS (version 13.0).
RESULTS AND DISCUSSION
37.5% (n=9) of participants in the present study were taking one or more DS during the past year. According to European Prospective Investigation into Cancer (EPIC) study there are marked differences in the use of DS in Europe with a strong North-South gradient among ten European countries participating in the study: the highest use of DS was found in Scandinavia and the lowest-in the Mediterranean. These geographical differences in DS use could be explained by cultural and behavior differences between European countries. (1) A variety of reasons, including anticipating physicians' disinterest, anticipating a negative response from physicians, or assuming that physicians lacked sufficient knowledge and other are discussed in connection with the low level of patients' disclose regarding alternative means of treatment. (31-33) Among respondents not sharing their DS use with physicians in our study 42.9% state as the leading reason for this "there is not enough time during the visits". The remaining part of respondents indicate that failure to disclose was due to " doctors do not ask" (28.6%) or because of personal conviction that "it is not necessary to inform physicians about DS intake" (28.6%). Physicians' disinterest and patients' belief that there is no need to inform health care professionals appear to be leading reasons for the low rate of disclosure in prior studies of DS use. In another study a significant proportion of patients indicate time restictions during the visits as a third main reason for non-disclosure. ( Inquaring all respondents in the study "During your visits does your doctor ask you about DS intake?" 45.8% of participants answered "never", 33.3%-"very rarely" and 20.8%-"rarely".
Some other studies suggest that the majority of patients were not asked whether they accept DS during hospitalization or medical visits. (41, 42) Insufficiency of knowledge, difficulties in obtaining valuable information, and the fact that DS are incongruous with the regulation of medicines can justify the reluctance of physicians to discuss such matters with their patients. It is unrealistic to expect from physicians to convey complete information about DS and to seek information about obscure supplements during timeconstrained office visits. However, regardless of their level of knowledge about an individual supplement or DS at all, physicians should consider even more general information. Physicians must be cognizant of the potential adverse reactions and interactions of DS with various prescribed drugs. They must be vigilant on the causal relationship between the use of DS and the occurrence of adverse events. Many patients falsely believe that DS are subject to the same rigorous control as drugs. Touching upon regulatory issues physicians can help their patients to make an informed choice about DS use. (18, 32) 
CONCLUSION
The present study is not intended as a commentary on the benefits or risks of DS or on the potential role of these products in patient care. Outstanding widespread use of DS is a sufficient reason for a more thorough analysis of the problems associated with DS use. Albeit preliminary, our results indicate a gap of physician-patient communication about DS intake. The weakness in legislation and cumbersome regulatory changes regarding DS highlight the importance of building a new type of relationship between patients and physician as a factor in reducing the risks associated with the use of DS. Healthcare professionals need to ask patients about DS intake. Patients need to be informed that sharing DS intake may be needful in safeguarding their health.
LIMITATIONS OF THE STUDY
The small sample size limits the statistical analysis of results and their generalizability. The study considered only patients' perspective. Most studies on patient-physician communication are on hospitalized patients and patients with chronic diseases, which hinder the comparability of results. This study is a pilot and our results are preliminary. Further investigation is needed to increase sample size for a thorough analysis of both physician-patient communication and other problems related to the use of DS. 
